Skip to Content
Is technology key to beating breast cancer? Learn more >

Afinitor (everolimus) Disease Interactions

There are 7 disease interactions with Afinitor (everolimus):

Major

Everolimus (Includes Afinitor) ↔ Liver Disease

Severe Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Everolimus exposure was increased in patients with mild (Child-Pugh class A), moderate (Child-Pugh class B), and severe (Child-Pugh class C) hepatic impairment. In patients with mild or moderate hepatic impairment, a dose reduction is recommended. Patients with severe hepatic impairment, everolimus may be used at a reduced dose if the desired benefit outweighs the risk.

Major

Everolimus (Includes Afinitor) ↔ Renal Disease

Severe Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Cases of renal failure, including acute renal failure and elevations of serum creatinine and proteinuria, some with a fatal outcome, have been observed in patients treated with everolimus. Therapy with everolimus should be administered cautiously in patients with renal dysfunction, in particularly where patients have additional risk factors that may further impair renal function. Renal impairment is not expected to influence drug exposure, and no dosage adjustment of everolimus is recommended in patients with renal impairment. Monitoring of renal function, including measurement of blood urea nitrogen (BUN), urinary protein, or serum creatinine, is recommended prior to the start of therapy and periodically thereafter.

Moderate

Everolimus (Includes Afinitor) ↔ Blood Glucose

Moderate Potential Hazard, Moderate plausibility

Applies to: Diabetes Mellitus

Elevations in serum blood glucose levels have been reported in patients taking everolimus. Monitoring of fasting serum glucose levels is recommended prior to the start of everolimus therapy and periodically thereafter. Clinicians should achieve control of glucose levels before initiating therapy with this agent.

Moderate

Everolimus (Includes Afinitor) ↔ Cholesterol

Moderate Potential Hazard, Moderate plausibility

Applies to: Hyperlipidemia

Elevations in cholesterol and triglyceride levels have been reported in patients taking everolimus. Monitoring of fasting lipid profile is recommended prior to the start of everolimus therapy and periodically thereafter. Clinicians should achieve control of lipid levels before initiating therapy with this agent.

Moderate

Everolimus (Includes Afinitor) ↔ Hematologic Abnormalities

Moderate Potential Hazard, Moderate plausibility

Applies to: Immunodeficiency

Hematologic abnormalities, including decreased levels of hemoglobin, lymphocytes, platelets, and white blood cell have been observed in patients taking everolimus. Caution is recommended when treating patients predisposed to hematologic changes. Periodic monitoring of complete blood count is recommended before starting therapy and periodically thereafter.

Moderate

Everolimus (Includes Afinitor) ↔ Infections

Moderate Potential Hazard, Moderate plausibility

Applies to: Infection - Bacterial/Fungal/Protozoal/Viral

The immunosuppressant effect of everolimus may decrease host resistance to infectious agents and may predispose patients to bacterial, fungal, viral, or protozoal infections, infections with opportunistic pathogens, and reactivation of hepatitis B virus. Therapy with this agent should be administered with caution in patients with an infection, particularly active infections or any untreated systemic fungal, bacterial, parasitic, or viral infection. It is recommended to complete the treatment of preexisting invasive fungal infections prior to starting treatment and if a diagnosis of invasive systemic fungal infection is made during treatment, discontinue and treat with appropriate antifungal therapy.

Moderate

Everolimus (Includes Afinitor) ↔ Vaccination

Moderate Potential Hazard, Moderate plausibility

Applies to: Vaccination

The administration of live vaccines should be avoided during everolimus therapy. It is recommended that close contact with individuals who have received live vaccines should be avoided because of the potential risk for shedding from the household contact and transmission to patient. It is recommended to be up-to-date with all required immunizations, as recommended by current immunization guidelines, before initiating therapy with everolimus.

Afinitor (everolimus) drug Interactions

There are 334 drug interactions with Afinitor (everolimus)

Afinitor (everolimus) alcohol/food Interactions

There are 2 alcohol/food interactions with Afinitor (everolimus)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide